PEB - Pacific Edge Ltd

[jimdog31]

Hmmmm - itching to get rid of all the shares he has accumulated?

Hmmm is right.

[Greekwatchdog]

For Bars updated this morning. No change to target price
OUTPERFORM
Pacific Edge (PEB) announced coverage from United Healthcare, the largest US private health insurer — another important
external validation in the key US market for its bladder cancer tests. The market opportunity is extensive and we see PEB as
well positioned to capitalise on this. There is no short-cut to changing clinical practice and the hard work is far from over,
however, recent key milestones have helped to prove up the commercial model and lower the risk. With the range of
justifiable long-term outcomes wide, we expect the share price to continue to be driven by newsflow — which is likely to be
positively skewed as further commercial progress follows recent success. OUTPERFORM.
Recent commercial milestones in the key US market
We have no visibility on price, however, expect both will be above that of public health insurer, CMS (price of US$760/test).
No change to forecasts, but helps to provide further confidence in medium-term outlook
We have not made any changes to our forecasts; our base case already incorporates progress with private insurers. However, as PEB
continues to make further commercial progress this helps to increase our confidence in the revenue path, and lower the risk. Being ‘in
network’ (or under coverage) with US payors will materially speed up the time to cash collection and reduce leakage (where cash is
never collected). This should also see test numbers better match revenue in time.
Share price responsive to newsflow
PEB's share price is highly responsive to newsflow, with the strong spike post the United Healthcare announcement returning the
stock to its recent high (late December 2020) after a period of steady decline. The path from here will unlikely be straight, however,
we expect newsflow to be positively skewed. This includes: new commercial agreement(s), stronger mention/inclusion in clinical
guidelines, back payment from US public health insurer CMS (for tests done ahead of securing reimbursement), additional.

[winner69]

Hmmmm - itching to get rid of all the shares he has accumulated?

Hey balance - We should make a list of his most famous davidisms and put them in a farewell card.

Remember when he used 'exciting' 22 times in one announcement

[sunnysleeper11]

Hmmmm - itching to get rid of all the shares he has accumulated?

yep - and so he should
he's done quite an extraordinary job with this company

[winner69]

Forbar finally caught on to the game -- PEB's share price is highly responsive to newsflow,

yep, instos ring Dave up and say 'hey Dave, share price declining so put out another announcement, even if its just what you said before but said in another way ... as long as its positive.@

[calledone]

How old is DD?

[winner69]

How old is DD?

I'd goes mid to late 50's

Maybe he's going back to Arborgen

[Balance]

Hey balance - We should make a list of his most famous davidisms and put them in a farewell card.

Remember when he used 'exciting' 22 times in one announcement

In all seriousness, why would any CEO leave a company just ‘when’ it is on the verge of real glory?

Must say it has got me scratching my head and evaluating my position.

Change ‘when’ to ‘if’ maybe?

[winner69]

In all seriousness, why would any CEO leave a company just ‘when’ it is on the verge of real glory?

Must say it has got me scratching my head and evaluating my position.

Change ‘when’ to ‘if’ maybe?

That was my first thought as well

[calledone]

In all seriousness, why would any CEO leave a company just ‘when’ it is on the verge of real glory?

Must say it has got me scratching my head and evaluating my position.

Change ‘when’ to ‘if’ maybe?

The news said he will continue in a consultation role after stepping down as CEO, so he may not be leaving as just yet. Anyway the retirement as CEO is in April 2022.